Gabapentin Capsule
Product Images NDC 71335-2004

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba-fig-1-jpg.jpg (Gaba Fig 1 Jpg)

Line graph shows mean pain scores over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. Two periods are indicated: a 4-week dose titration period and a 4-week fixed dose period. Gabapentin's mean pain score decreases more over time than placebo, starting around 6 and dropping to about 4 by week 8, while placebo remains near 6.*

FDA Label Image

Gaba-fig-2-jpg.jpg (Gaba Fig 2 Jpg)

A line graph depicting mean pain score over time in weeks during a 3-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo with Gabapentin at 1800 mg/day and 2400 mg/day dosages. The y-axis shows mean pain score from 0 to 10, and the x-axis shows weeks from baseline to 7.*

FDA Label Image

Gaba-fig-3-jpg.jpg (Gaba Fig 3 Jpg)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) dosages in two separate studies. Study 1 shows 12% and 29% responders for placebo and GBP 3600 mg, respectively. Study 2 shows 14%, 32%, and 34% responders for placebo, GBP 1800 mg, and GBP 2400 mg, respectively, with significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Gaba-fig-4-jpg.jpg (Gaba Fig 4 Jpg)

A scatter plot chart showing the percentage difference on the y-axis versus daily dose in mg on the x-axis, ranging from 600 to 1800 mg. The chart includes data points for three studies labeled a, b, and c, each represented by different squares in black, grey, and white respectively, showing varied differences at different dose levels.*

FDA Label Image

Gaba-structure.jpg (Gaba Structure)

Chemical structure of gabapentin showing a cyclohexane ring connected to an amino group and a carboxymethyl group, illustrating the molecular arrangement of the active ingredient.*

FDA Label Image

Gabapentin-formula-jpg.jpg (Gabapentin Formula Jpg)

Mathematical formula for calculating creatinine clearance (CLCr) based on age (years), weight (kg), serum creatinine (mg/dL), and a gender adjustment factor for female patients. This panel is part of pharmacokinetic or dosing information related to gabapentin capsules, 300 mg, by Bryant Ranch Prepack.*

FDA Label Image

Label (Lbl713352004)

Label for Gabapentin 300 mg capsule by Bryant Ranch Prepack, with a comparison to Neurontin 300 mg capsule by Granules India Limited. The label indicates the capsule is yellow (white opaque body, yellow opaque cap), includes a lot number, storage instructions at 20°-25°C, a caution on dizziness, and a note to keep it out of reach of children. The package contains 90 capsules and displays the NDC 71335-2004-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.